Costantino Henry R, Illum Lisbeth, Brandt Gordon, Johnson Paul H, Quay Steven C
Nastech Pharmaceutical Company, Inc., Bothell, WA 98021, USA.
Int J Pharm. 2007 Jun 7;337(1-2):1-24. doi: 10.1016/j.ijpharm.2007.03.025. Epub 2007 Mar 25.
Interest in intranasal (IN) administration as a non-invasive route for drug delivery continues to grow rapidly. The nasal mucosa offers numerous benefits as a target issue for drug delivery, such as a large surface area for delivery, rapid drug onset, potential for central nervous system delivery, and no first-pass metabolism. A wide variety of therapeutic compounds can be delivered IN, including relatively large molecules such as peptides and proteins, particularly in the presence of permeation enhancers. The current review provides an in-depth discussion of therapeutic aspects of IN delivery including consideration of the intended indication, regimen, and patient population, as well as physicochemical properties of the drug itself. Case examples are provided to illustrate the utility of IN dosing. It is anticipated that the present review will prove useful for formulation scientists considering IN delivery as a delivery route.
作为一种非侵入性给药途径，鼻内（IN）给药的关注度持续迅速增长。鼻粘膜作为药物递送的靶组织具有诸多优势，例如给药表面积大、药物起效快、有递送进入中枢神经系统的潜力且无首过代谢。多种治疗性化合物都可通过鼻内给药，包括相对较大的分子如肽和蛋白质，尤其是在有渗透促进剂存在的情况下。本综述深入讨论了鼻内给药的治疗方面，包括对预期适应症、给药方案和患者群体的考量，以及药物本身的物理化学性质。提供了案例以说明鼻内给药剂量的实用性。预计本综述将对考虑将鼻内给药作为一种给药途径的制剂科学家有用。
